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We investigated the mode of action of PNU-120596, a type II positive allosteric modulator of the rat a7
nicotinic acetylcholine receptor expressed by GH4C1 cells, using patch-clamp and fast solution exchange.
We made two important observations: first, while PNU-120596 rapidly associated to desensitized re-
ceptors, it had at least hundredfold lower affinity to resting conformation, therefore at 10 mM confor-
mation it dissociated from resting receptors; and second, binding of PNU-120596 slowed down
dissociation of choline molecules from the receptor radically. We propose that when agonist concen-
tration is transiently elevated in the continuous presence of the modulator (as upon the neuronal release
of acetylcholine in a modulator-treated animal) these two elements together cause occurrence of a cycle
of events: Binding of the modulator is limited in the absence of the agonist. When the agonist is released,
it binds to the receptor, and induces desensitization, thereby enabling modulator binding. Modulator
binding in turn traps the agonist within its binding site for a prolonged period of time. Once the agonist
finally dissociated, the modulator can also dissociate without re-binding, and the receptor assumes its
original resting conformation. In kinetic simulations this “trapped agonist cycle” mechanism did not
require that the orthosteric and allosteric ligands symmetrically modify each other’s affinity, only the
modulator must decrease agonist accessibility, and the agonist must induce a conformation that is
accessible to the modulator. This mechanism effectively prolongs and amplifies the effect of the agonist.
 2014 Published by Elsevier Ltd.93
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1091. Introduction
The a7 subunit containing subtype of nicotinic acetylcholine
receptor (a7 nAChR) is abundant in the CNS, and also present in
many non-neural tissues. It is involved in the regulation of growth
and differentiation in general, and in synaptic plasticity in partic-
ular. Pro-cognitive, anti-ischemic, anti-inflammatory, and anti-
nociceptive effects of its agonists and positive allosteric modulators
(PAMs) make this receptor a promising target in a number of dis-
orders including Alzheimer’s disease, schizophrenia, Parkinson’s
disease, chronic pain, inflammatory diseases and even myocardial
infarction (AhnAllen, 2012; Costa et al., 2012; Freitas et al., 2013;
Isaacson et al., 2013; Li et al., 2013; Liu and Su, 2012; Mazurov
et al., 2012; Russo and Taly, 2012; Vizi et al., 2010; Williams et al.,
2011b; Xiong et al., 2012).nic acetylcholine receptor;
(5-methylisoxazol-3-yl)urea;
ion exchange time; AUC, area
36 12109423.
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//dx.doi.org/10.1016/j.neuropAgonists and positive allosteric modulators (PAMs) of the a7
nAChR are prospective pro-cognitive drugs in different types of
dementia, and in schizophrenia. Several pre-clinical and clinical
studies have demonstrated their effectiveness (AhnAllen, 2012;
Faghih et al., 2007, 2008; Mazurov et al., 2012; Williams et al.,
2011b). Two major classes of PAMs are known (Gronlien et al.,
2007; Williams et al., 2011b): type I PAMs increase the amplitude
of currents, but do not significantly modify their kinetics, while
type II PAMs profoundly change the kinetics of currents, by radi-
cally prolonging single channel open times. The advantage of PAMs
over agonists is that the physiological spatio-temporal pattern of
neuronal activation is preserved; the modulators only augment a7
nAChR-mediated signals. This pharmacological approach has been
proven to be successful in the case of GABAA receptors (benzodi-
azepines and barbiturates). In the case of a7 nAChRs, however,
much less is known about the mode of action of PAMs, and most
PAM compounds have only been developed recently. One of the
most studied type II PAMs is the compound PNU-120596. The last
few years brought some impressive results regarding the mode of
action of PNU-120596, such as the effect of the drug on the single
channel behavior of the receptor (daCosta et al., 2011; Williams
et al., 2011a), the state-dependence of PNU-120596 effect117
118
119
the positive modulator PNU-120596 on a7 nicotinic acetylcholine
harm.2014.01.033
Fig. 1. Co-application of 10 mM choline and 10 mM PNU 120596 (black traces) using
submillisecond solution exchange. Inset shows the fast component at an expanded
time scale. Gray traces show 10 mM choline application for comparing the fast
component to the choline-evoked current.
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NP5391_proof ■ 1 February 2014 ■ 2/13(Isaacson et al., 2013; Wang et al., 2012; Williams et al., 2011a),
and the temperature-dependence of both receptor gating, and
PNU-120596 action(Jindrichova et al., 2012; Sitzia et al., 2011;
Williams et al., 2012). Nevertheless, some very basic aspects of
the effect of PNU-120596 on receptor function are still not fully
understood (Bouzat et al., 2008; daCosta et al., 2011; Papke et al.,
2009; Williams et al., 2011a,b). We investigated the following
specific questions: What is the mechanism behind the distinctive
biphasic curve observed when agonists are applied in the presence
of PNU-120596 (Gronlien et al., 2007;Malysz et al., 2009b)? Is there
a difference in the affinity of PNU-120596 to different conforma-
tional states of the receptor? The receptor has been shown to have
distinct desensitized states, which have different sensitivity to
PNU-120596 (Papke et al., 2009; Uteshev et al., 2002; Wang et al.,
2012; Williams et al., 2011a). Can we detect this difference? Can
the modulator bind to the resting receptor? How can the effect of
PNU-120596 be explained in terms of influencing conformational
transition rates? Does it increase the affinity of the agonist? The
possible cooperativity between agonist and PAM is controversial
(daCosta et al., 2011;Williams et al., 2011b). An apparent increase in
agonist affinity is obvious (Hurst et al., 2005), but it must be un-
derstood that agonist-evoked current amplitudes misrepresent
concentrations because the rate of solution exchange is insufficient
as compared to the fast gating of the channel (Papke et al., 2000;
Papke and Thinschmidt, 1998). Slowing down current kinetics
would inevitably cause an increase of apparent affinity, therefore it
is not clear whether type II PAMs indeed induce a conformational
change of the orthosteric site that increases its affinity, or rather
they only reveal its true affinity by slowing gating kinetics. Finally,
the opposite interaction is also unsettled: whether the agonist has
an effect on the affinity of the PAM binding site, i.e., whether the
cooperativity between agonist and PAM must inevitably be
mutual?
Our aimwas to extend the kinetic model of agonist action on a7
nAChR described in the accompanying paper (Pesti et al.) by
incorporating PNU-120596-bound states as well, in the hope that
our attempt to reproduce experimentally observed phenomena
may give an insight into possible mechanisms involved in the ac-
tion of PNU-120596 on a7 nAChRs.
2. Materials and methods
2.1. Materials
PNU-120596 was obtained from Tocris Bioscience (Bristol, UK). Cell culture
products were obtained from Life Technologies. All other chemicals were obtained
from Sigma.
2.2. Cell culture
GH4C1 cells stably transfected with pCEP4/rat a7 nAChR were obtained from
Siena Biotech S.p.A. (Siena, Italy). Cells were cultured in poly-L-lysine coated Petri
dishes using HAM’s F10 medium supplemented with 15% horse serum, 2.5% foetal
bovine serum,1% penicillinestreptomycin,1mMGlutaMAX,100 mg/ml Hygromycin B.
2.3. Electrophysiology
Electrophysiological recordings were done as described in the accompanying
paper (Pesti et al.). Briefly, an Axopatch 200B amplifier and the pClamp software
were used to acquire whole-cell or outside-out patch currents at a holding potential
of 70 mV. Currents were digitized at 20 kHz and filtered at 10 kHz; for illustration
purposes some of the traces were off-line filtered digitally at 2 kHz. The composition
of pipette solution was (in mM): CsCl 55, CsF 65, EGTA 10, HEPES 10 (pH ¼ 7.2), the
extracellular solution contained (in mM): NaCl 140, KCl 5 CaCl2 2, MgCl2 1, Glucose 5,
and HEPES 5 (pH ¼ 7.3). Solution exchange was performed by the “liquid filament
switch” method as described in the accompanying paper (Pesti et al.). Briefly: theta
glass tubes (1.5 mm O.D.) were pulled to have a tip diameter between 150 and
250 mm and Microfil capillary (0.35 mm OD) was inserted into both sides. The
solution reservoirs were connected to the pressure control unit of a DAD-12 solution
exchange system (ALA Scientific Instruments Inc., Farmingdale, NY), this
allowed optimization of flow velocity (typically 5e20 cm/s). Translational velocity
was 1e5 cm/s. Voltage command waveforms for the piezoelectric actuator (BurleighPlease cite this article in press as: Szabo, A.K., et al., Mode of action of
receptors, Neuropharmacology (2014), http://dx.doi.org/10.1016/j.neuropLSS-3200 system) were written in the pClamp software. Ten to ninety % solution
exchange times (SXTs) for individual measurements were determined using open-
tip junction potential measurement right after the experiments, without moving
the pipette; the values were between 0.5 and 2ms. Time constants of the removal of
channel block confirmed that solution exchangewas not significantly delayed by cell
geometry or unstirred layer effect.
2.4. Simulations
The simulation was based on a set of differential equations with the occupancy
of each receptor state (i.e., the fraction of the receptor population in that specific
state) given by the following equation
dSiðtÞ
dt
¼
Xn
j

SjðtÞ*kji  SiðtÞ*kij

where Si(t) is the occupancy of a specific state at the time t, Sj(t) is the occupancy of a
neighboring state, n is the number of neighboring states, and kij and kji are the rate
constants of transitions between neighboring states. Simulations were performed
using Berkeley Madonna v8.0.1 (www.berkeleymadonna.com), or QuB (www.qub.
buffalo.edu) (Milescu et al., 2000e2013).
2.5. Analysis of data
Monoexponential fitting: I(t) ¼ (Imax  Imin)*exp(et/s) þ Imin was performed by
the Solver function of Microsoft Excel. Paired Student’s t test was used for statistical
analysis, unless otherwise mentioned. A probability level of 0.05 or less was
considered to reflect a statistically significant difference.
3. Results and discussion
3.1. Effect of PNU-120596 on choline-evoked currents
3.1.1. The biphasic nature of PNU-120596-modulated choline-
evoked currents
Co-application of 10 mM choline and 10 mM PNU-120596 pro-
duced a characteristic biphasic curve with an initial fast peak and a
subsequent prolonged activation. The biphasic nature of agonist
evoked currents in the presence of PNU-120596 has been observed
before (Gronlien et al., 2007; Malysz et al., 2009a), but the physical
processes which underlie the two phases of the response have not
been identified (Williams et al., 2011b). (We should mention that
prolonged co-application of PNU-120596 and ACh also produced a
biphasic pattern (Williams et al., 2011a), however, that is an
entirely different phenomenon, first because the amplitudes of the
two components are similar, and second because it occurs on the
time scale of minutes, not milliseconds.) It is important to note that
we applied the mixture of agonist and modulator at a 10e90% so-
lution exchange time (SXT) in the range of 0.5e2 ms, therefore the
initial part of the evoked current was better resolved. We made the
following observations: (i) while it was previously found that the
two phases merge at high PNU-120596 concentration (Gronlien
et al., 2007 e Fig. 2, Malysz et al., 2009a e Fig. 1, Malysz et al.,
2009b e Fig. 8; reviewed in Williams et al., 2011b), they were
clearly separated in our experiments even at 10 mM PNU-120596
(and 10 mM choline). The first phase decayed to 14.0  5.5%
(n ¼ 10) of the peak, before the rise due to the “secondary
component” could be detected (Fig. 1). (ii) The amplitude, as well asthe positive modulator PNU-120596 on a7 nicotinic acetylcholine
harm.2014.01.033
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NP5391_proof ■ 1 February 2014 ■ 3/13the rise and decay kinetics of the first component was identical
with the current evoked by 10mM choline alone (Fig.1), i.e., the rise
time was 0.39  0.03 ms, and the decay time constant was
1.01  0.13 ms. We assume that the onset rates for the effect of the
agonist choline and the modulator PNU-120596 differ, and using a
fast solution exchange, this difference can be resolved. Thus, the
first component reflects a pure choline-evoked current unaffected
by PNU-120596, and only during the later phase of the decay does
the effect of PNU-120596 begin to occur (the second component
takes several tens of milliseconds to fully develop). We suppose
that the rate limiting step for the first component must be solution
exchange rate. For the second component, the onset rate is known
to be dependent on PNU-120596 concentration (Gronlien et al.,
2007; Malysz et al., 2009b), but it is not clear which exact pro-
cesses are the major determinants of onset kinetics at high
modulator concentration. It may be partitioning of PNU-120596
into the membrane phase (being a lipophilic molecule, and prob-
ably having its binding site within the transmembrane domain of
the receptor (daCosta et al., 2011; Young et al., 2008), PNU-120596
probably accesses it from the membrane phase), but the binding
reaction itself, or any of the gating transitions might also limit onset
rate (this question is addressed below in Section 3.2.2). Note that
not only a low opening rate can limit the time constant of onset, but
any other gating rate involved in the process of activation (e.g.,
closing, desensitization), by affecting the rate of reaching a gating
equilibrium. Slower onset at lower PNU-120596 concentrations is
probably limited by concentration-dependent processes, such as
partitioning and binding.
3.1.2. Characterization of PNU-120596-modulated choline-evoked
currents
Because the first phase was identical with the current evoked by
choline alone, the positive modulator effect of PNU-120596 could
be assessed within a single biphasic trace. The modulator caused a
14.5  2.4 fold increase in amplitude (n ¼ 22; range: 3.3e47.9-fold;
median: 10.48-fold). In order to minimize series resistance error,
cells and patches, where the choline-evoked current amplitudewas
higher than 200 pA were excluded from this calculation. The
potentiation is somewhat larger than in the original paper that first
characterized the effect of PNU-120596 (Hurst et al., 2005), but we
used 10 mM PNU-120596 instead of 1 mM. On the other hand, the
effect we observed was less than the one described in other pub-
lications (Friis et al., 2009; Young et al., 2008). One of the reasons
for this may be that we used supramaximal choline concentration,
while potentiation is largest at low agonist concentrations.
Furthermore, in our experiments the responses to 10 mM choline
are fairly well resolved due to the fast solution exchange. Slower
solution exchange rates seriously decrease the amplitude of fast
choline-evoked currents, but do not affect the slow-onset currents
evoked by choline in the presence of PNU-120596; therefore the
potentiation seems larger with slower solution exchange.
We observed a characteristic current component at the end of
PNU-120596 and 10 mM choline co-application (Figs. 1e4). A
rebound current, which was 14.06  2.45% of the PNU-120596-
potentiated current in magnitude, appeared with a time constant
of 1.37  0.19 ms (this value was close to the solution exchange
rates we usually worked with, therefore the true onset kinetics of
this component could be even faster). The rebound current was
smaller (6.38  1.05%) when the concentration of choline co-
applied with 10 mM PNU-120596 was 1 mM, and it was undetect-
able at 100 mM choline, although the PNU-120596-potentiated
current was similar in amplitude within the range of 100 mMe
10 mM choline concentration (which means that for 100 mM
choline-evoked currents the potentiation is much larger). The
rebound current was also absent when co-application of 10 mMPlease cite this article in press as: Szabo, A.K., et al., Mode of action of
receptors, Neuropharmacology (2014), http://dx.doi.org/10.1016/j.neuropcholine and 10 mM PNU-120596 was terminated by continuing
perfusion of 10 mM choline only (see Section 3.1.3). These obser-
vations suggest that the rebound current was at least mostly due to
removal of channel block by choline molecules. In single channel
recordings, an immediate drop of single-channel noise was
observed by Williams et al. (2011a) upon removal of the agonist.
Although the single channel amplitude was not increased, an
apparent increase can be observed either if the traces are low-pass-
filtered at frequency lower than 10 kHz, or if activity of several
channels is recorded at the same time. We believe that the rebound
current we observed is the multi-channel equivalent of this drop in
noise in single-channel recordings.
3.1.3. Dissociation of choline and PNU-120596
We compared the decay after PNU-120596 and choline co-
application in three cases: i) When both the agonist and the
modulator were removed, ii) When the modulator was removed
while agonist perfusion continued, and iii) when the agonist was
removed while the modulator was still present. Examples for indi-
vidual traces as well as the averaged results of 15 -15 traces from
each of the three protocols are shown in Fig. 2. As we have
mentioned, the rebound component could only be seen when
choline was removed. Fitting the decay phases with the single
exponential function gave time constants 293.9  12.3 ms,
426.6  29.9 ms, and 2372  726.5 ms for full washout, PNU-
120596-removed-choline-present, and choline-removed-PNU-
120596-present scenarios, respectively (n ¼ 6 cells, using the av-
erages of 7e15 individual traces of all three protocols in each cell; all
three groups were significantly different from each other). In the
presence of PNU-120596 the current did not decay to baseline
within the 2.5 s of modulator application. At the end of this 2.5 s
period,when themodulatorwas also removed, the decay had a time
constant of 317.9  20.0 ms (not significantly different from the
decay rate during fullwashout). Themost striking phenomenonwas
the prominent deceleration of decay in the presence of PNU-120596
alone (p< 0.001, n¼ 6). Because PNU-120596 in itself cannot cause
activation of the receptor, we need to suppose that choline must
have been kept bound to the receptor throughout the slow decay,
and the decay rate primarily reflects the rate of choline dissociation.
The phenomenon has recently been studied on the level of single
receptor-mediated currents, where currents persisted for
2.57  0.2 s after removal of the agonist (Williams et al., 2011a),
which is very similar to the time constant we observed. The
decreased rate of choline dissociation may imply that PNU-120596
binding radically increases the affinity of choline to the receptor, but
it is also possible that the effect is on the accessibility, not the affinity
of the orthosteric binding site (i.e., both access and egress rates are
reduced as a consequence of PNU-120596 binding). As for the decay
in the presence of choline alone, it must, in contrast, reflect the
dissociation rate of PNU-120596. The time constant was somewhat
higher than at full washout (p< 0.01, n¼ 6), but the small difference
indicates that dissociation of the modulator was not strongly
delayed by bound agonist molecules. The mutual cooperativity,
which is predicted by the allosteric theory (see (Williams et al.,
2011b) for discussion) did not seem to be symmetrical: While
PNU-120596 caused a radical decrease in the rate of choline disso-
ciation, choline had no such effect, it rather seemed to interact with
PNU-120596 binding primarily by inducing desensitized confor-
mation of the receptor, which promoted PNU-120596 association
(for the state-dependence of association see also Section 3.1.4.).
3.1.4. Association of PNU-120596 to resting state
In order to understand themechanism of PNU-120596 action on
a7 nAChRs, we need to know if PNU-120596 has a preference to-
ward certain states.the positive modulator PNU-120596 on a7 nicotinic acetylcholine
harm.2014.01.033
Q1
Fig. 2. The decay after 10 mM choline and 10 mM PNU-120596 co-application (A) Full washout, (B) washout of PNU-120596, and (C) washout of choline. Gray lines show five
individual traces, Black lines show the average of 15 traces. (D) The average traces plotted on the same figure: full washout (light gray), washout of PNU-120596 (black) and washout
of choline (dark gray).
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NP5391_proof ■ 1 February 2014 ■ 4/13Let us consider a simple triangular scheme of resting, open and
desensitized receptor (see Scheme 2 in the accompanying paper
(Pesti et al.)), and draw a parallel triangle of PNU-120596-bound
states (only a single agonist occupancy level is shown, where “n”
of the five binding sites are occupied), similarly to the schemeFig. 3. Pre-incubation with 10 mM PNU 120596 did not significantly decrease the
amplitude of the first current phase. A family of currents evoked by co-application of
10 mM choline and 10 mM PNU-120596, after different durations of PNU-120596 pre-
incubation: 15, 215, 415, 615, 815, 1015, and 1215 ms. Inset shows the first phase at an
expanded time scale.
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receptors, Neuropharmacology (2014), http://dx.doi.org/10.1016/j.neurop(Fig. 7) shown in the work of daCosta et al. (2011): (Scheme 1)
where “p” indicates PNU-120596-bound states. For the sake of
simplicity, we do not consider differentmodulator occupancy levels
(monoliganded, diliganded, etc; the receptor probably has five
PNU-120596 binding sites), only bound and unbound states. Since
we used supramaximal PNU-120596 concentration, we suppose
that the majority of binding sites were occupied in the presence of
the drug.
We aimed to determine, to which of the three states we can
assume substantial PNU-120596 association. Association to resting
state (anR) can be tested by pre-application of PNU-120596. If as-
sociation to anR is possible, then during PNU-120596 application a
significant fraction of the receptors will bind the modulator, and be
accumulated in panR state. When receptors are in the panR state,
the characteristic rapid agonist-induced activation of PNU-120596-
unbound receptors (anR to anO) is impossible, because the current
rise time is determined by the gating rate constants (opening rate,
closing rate, desensitization rate, etc.) which are drastically slowed
down by PNU-120596 binding. Therefore, if a significant fraction of
the receptors are in panR state, the first rapid component of thethe positive modulator PNU-120596 on a7 nicotinic acetylcholine
harm.2014.01.033
Fig. 4. Re-application of agonists. (A) Re-application after 10 mM PNU-120596 perfusion. Boxed areas are shown overlayed in the upper left panel of (C). (B) Re-application after
washout. Boxed areas are shown overlayed in the lower left panel of (C). (C) Examples for currents evoked by the first (gray line) and second (black line) pulse of agonists, after
3200 ms perfusion of either 10 mM PNU-120596 (upper panel), or control extracellular solution (lower panel). Only the initial part is shown, to allow comparison of fast current
components. (D) The recovery of the fast current component plotted against the decay of the slow current component (agonist-and-modulator-induced activity). Average and SEM
values from n ¼ 5 or 6 individual cells. On the x axis zero indicates full relative amplitude, while 1 indicates fully decayed slow current component. Decay of the slow component
indicates partial or full dissociation of ligands and transition into one of the non-conducting states. Recovery of the fast component, on the other hand, indicates the ratio of fully
unbound and recovered receptors. The latter lags behind the former, as shown by the extent of deviation from the diagonal.
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Scheme 3. Proposed predominant pathway traveled by the receptors upon PNU-
120596 pre-application followed by choline and PNU-120596 co-application.
anO 
anR anD 
panO 
panR panD 
Scheme 1. Three-state model of the a7 nAChR with PNU-120596-bound states.
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NP5391_proof ■ 1 February 2014 ■ 6/13current must be significantly decreased. The predominant route for
this mechanism is illustrated in Scheme 2.
However, what we found in PNU-120596 pre-application ex-
periments was just the opposite. A typical recording is shown in
Fig. 3, with currents evoked after pre-application times 15, 215, 415,
615, 815, 1015, and 1215ms. Pre-application of PNU-120596 left the
first current phase essentially unchanged (a non-significant
9.4  5.0% decrease was observed; n ¼ 5), while the second
phase was significantly accelerated. With the shortest, 15 ms PNU-
120596 pre-application (for technical reasons we could not use
0 ms pre-application) the onset of the second phase occurred with
a time constant of 115.1  41.1 ms (monoexponential fitting; range:
30.6e286 ms). After 615 ms of PNU-120596 pre-application the
onset of the second phase was accelerated, and could no more be
fitted with a monoexponential function. A fast time constant of
10.7  2.3 ms appeared, which constituted 54.9  5.8% of the
amplitude, and the slow time constant was also accelerated: it was
53.3  19% ms (range: 21.9e139 ms). Although the cell-to-cell
variance in the time constants of onset was considerable, the ac-
celerationwas evident in all cases, and even the slow time constant
was significantly shorter (2.18  0.38 fold difference; p < 0.05,
n ¼ 5) after 615 ms pre-application than after 15 ms pre-
application. Longer pre-applications (up to 80 s) did not further
accelerate the second phase of activation, and did not further
decrease the amplitude of the first current phase. After 80 s of pre-
incubation the first phase amplitude was still unchanged (we
observed a non-significant 5.1  4.3% decrease; n ¼ 5).
We propose therefore, that the predominant route traveled by
the receptors is via desensitized states, as illustrated in Scheme 3.
What can be the mechanism of acceleration, if we suppose that
it is not due to association of PNU-120596 to its binding site? We
know that the binding site of PNU-120596 is within the trans-
membrane domain of the receptor, and we also know that the
molecule is lipophilic (its calculated logP value is 2.57). We propose
that PNU-120596 might access its binding site from the membrane
phase. Partitioning into, and accumulation within the membrane
may be the process that requires a few hundred milliseconds. Once
the equilibrium of partitioning has been reached and the mem-
brane phase is saturated, binding can occur at a higher rate.
The partial merging of the two components seen upon pro-
longed PNU-120596 pre-application (Fig. 3) is not likely to be due
to direct association to open channels (anO to panO transition).
Because the dwell time in anO is extremely short (less than 100 ms
(daCosta et al., 2011; Williams et al., 2011a)) and the open proba-
bility is extremely low, it is unlikely that a significant fraction of
PNU-120596 association would occur to open receptors.anO 
anR anD 
panO 
panR panD 
Scheme 2. Hypothetical predominant pathway traveled by the receptors upon PNU-
120596 pre-application followed by choline and PNU-120596 co-application.
Please cite this article in press as: Szabo, A.K., et al., Mode of action of
receptors, Neuropharmacology (2014), http://dx.doi.org/10.1016/j.neuropIn summary, association to open and resting states are probably
negligible, and so is the occupancy of PNU-120596-bound resting
state (panR) itself. This, together with the reasoning for preferring
Scheme 4 over Scheme 3 of the accompanying paper (Pesti et al.)
gives the following simplified scheme:1213.1.5. Re-application of agonists
We have argued that association to resting state must be much
slower than to desensitized state. The more important question is,
however, whether modulator association to resting receptors oc-
curs at all? (Under in vivo conditions, where the modulator would
have plenty of time to associate, a mere slowing of association
would not make much difference.) The question is not the kinetics,
but the equilibrium. We investigated, therefore, the situation when
we start from full modulator occupancy (10 mM PNU-120596 co-
applied with the agonist), then wash out the agonist while the
modulator is continually present, and then test whether dissocia-
tion of themodulator occurred by re-application of the agonist. This
experiment can be viewed as the combination of the protocols
described in Sections 3.1.3 (Fig. 2C) and 3.1.4 (Fig. 3). The initial part
is identical with the one shown in Section 3.1.3, but then, the
agonist is re-applied ande as it was discussed in Section 3.1.4e the
ratio of modulator-unbound receptors is tested by measuring the
magnitude of the first fast current component. Control experiments
(as in Fig. 2A) with full washout between agonist-plus-modulator
pulses were also done for comparison.
As we have shown in Section 3.1.3, after washing out choline,
but keeping PNU-120596 present, the current decayed slowly to-
wards the baseline. The decay is certainly due to the dissociation of
the agonist, but what happens with the modulator is uncertain.
Modulator molecules may immediately dissociate from agonist-
unbound receptors, or they may stay bound to the receptors. If
the modulator stayed bound, then upon re-application of the
agonist, we would only see agonist-modulated openings, i.e.,
delayed activation. If, however modulator molecules also dissoci-
ated from receptors that had been deserted by agonist molecules,
than we would see the re-appearance of the fast first current
component (see Section 3.1.4). The magnitude of the fast compo-
nent, therefore, will reflect howmuch of the receptors have already
lost their modulators.
We used different interpulse intervals (100, 200, 400, 800, 1600,
3200, and 6400 ms), which allowed us to test the magnitude of the
fast current component at different times during the decay. An
experiment with 1 mM ACh as agonist is shown in Fig. 4A, an
example for a control experiment is shown in Fig. 4B. We did not ofanO 
anR anD 
panO 
panD 
Scheme 4. Minimal model of PNU-120596 action at a single agonist occupancy level.
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NP5391_proof ■ 1 February 2014 ■ 7/13course expect that the decay of the slow current component will be
exactly paralleled by the increase in the fast component, not even in
the control case, because after dissociation of either the agonist or
the modulator, the receptor needs additional time to recover into
resting state. Instead, we compared how the increase of the fast
component followed the decay of the slow current, and compared
this in control experiments (extracellular solution perfused be-
tween pulses) and PNU-120596 unbinding experiments (10 mM
PNU-120596 perfused between pulses). Comparison of currents
evoked by the first and the second pulse with 3200 ms interpulse
interval are shown in Fig. 4C, for 1 mM ACh (left panel), 10 mM ACh
(middle panel) and 10 mM choline (right panel). PNU-120596 un-
binding experiments are shown in the upper panel, while control
experiments in the lower panel. The 3200 ms interpulse interval
was chosen for illustration, because at this interval the slow
component has not yet decayed to baseline in the case of PNU-
120596 unbinding experiments (hence the shifted baseline in
Fig. 4C, upper panel), but the fast component is already evident.
Dashed lines indicate extrapolation of the slow component to the
starting point of the current, to enable measurement of amplitudes
in cases when there was a considerable overlap between fast and
slow components. We could observe, that in spite of 10 mM of
PNU-120596 being continuously present, the fast phase re-
occurred with essentially unchanged kinetics. The onset rate of
the slow component was significantly increased after prolonged
PNU-120596 perfusion. The control onset rate showed considerable
variance (ranging from 63 to 719 ms), but PNU-120596 perfusion
always significantly accelerated it. For the 6400 ms interpulse in-
terval the 2nd/1st pulse ratio of slow onset time constants was
0.63  0.17, 0.59  0.23 and 0.59  0.16 for 1 mM ACh, 10 mM ACh
and 10 mM choline, respectively. The 2nd/1st pulse ratios for
control experiments were 0.97  0.08, 0.85  0.09 and 0.97  0.06
for the same agonists. To illustrate how the recovery of the fast
component follows the decay of the slow component, we plotted
the fractional recovery of the fast component against the fractional
decay of the slow component (Fig. 4D). The plots for control vs.Fig. 5. The effect of PNU 120596 decreased after prolonged choline application. (A) Upper p
PNU 120596 (black bars). Choline was applied for 15, 95, 175, 335, 655, 1295 and 2575 ms
currents at an expanded time scale. Arrows indicate comparison of slow desensitization
development of insensitivity to PNU 120596 in the presence of 10 mM choline. Black line s
Please cite this article in press as: Szabo, A.K., et al., Mode of action of
receptors, Neuropharmacology (2014), http://dx.doi.org/10.1016/j.neuropPNU-120596 experiments were not significantly different with
either of the agonists used. This suggests that the rate-limiting step
must be agonist dissociation. Once the agonist dissociation has
occurred, modulator molecules also rapidly dissociate, and the re-
ceptor resumes its agonist-unbound, modulator-unbound resting
state relatively rapidly. At the moment we cannot answer the
question of how many modulator molecules need to dissociate for
the receptor to resume resting state. Recent investigations on PNU-
120596-resistant mutants suggest that partially occupied receptors
may produce a kinetics similar to that of the modulator-unbound
receptor (daCosta and Sine, 2013). The extent of modulator disso-
ciation from all five binding sites may not exactly match the re-
covery of the fast component, but this does not change our
conclusion, that modulator molecules cannot stay bound to
agonist-unbound receptors.
3.1.6. Association of PNU-120596 to different desensitized states
As we have discussed in the accompanying paper (Pesti et al.), it
has been observed in different laboratories, that after prolonged
exposure to agonists recovery was more delayed (Uteshev et al.,
2002; Wang et al., 2012; Williams et al., 2011a,b), which suggests
that more than one desensitized conformational states of a7 nAChR
must exist.
We investigated if PNU-120596 had identical effect on different
desensitized states. PNU-120596 (10 mM) and choline (10 mM)
were co-applied after different durations of 10 mM choline appli-
cation. Longer durations of pre-exposure to choline caused re-
ceptors to progressively enter slow desensitized state. We expected
that if either the affinity to separate desensitized states or the ef-
ficacy to reactivate receptors from these states is different, then the
effect of PNU-120596 would depend on the duration of previous
choline exposure. Prolonged choline exposure caused receptors to
become progressively less sensitive to the positive modulation by
PNU-120596. Fig. 5A illustrates a typical family of currents evoked
by choline pre-applications of different durations (15, 95, 175, 335,
655, 1295 and 2575 ms), followed by co-application of PNU-120596anel illustrates the protocol: 10 mM choline (gray bars) and 10 mM choline with 10 mM
before co-application of the agonist with the modulator. Inset shows choline-evoked
in the absence and presence of PNU-120596 (see text). (B) The time course of the
hows bi-exponential fit to data points.
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NP5391_proof ■ 1 February 2014 ■ 8/13and choline. Note that the amplitude of the choline-evoked fast
current did not change throughout the experiment (see inset). The
mean decrease in amplitude (Fig. 5B; amplitudes were measured at
the peak of the rebound current component to exclude the effect of
channel block) was fit with a biexponential function, the time
constants were 353 ms (51% amplitude contribution) and 2379 ms
(49% amplitude contribution). Development of a PNU-120596-
insensitive desensitized conformation can occur not only in the
presence of the agonist alone, but also in the presence of both
choline and PNU-120596 (Williams et al., 2011a). In our experi-
ments this could be detected on the first four curves (15e335 ms
choline application), where the current started to decay after
reaching a maximal amplitude (Fig. 5A). Note however, that in the
presence of choline only, the development of this conformationwas
significantly faster. Compare for example the 1st and 6th traces at
w2 s after the start of agonist application (see arrows in Fig. 5A). In
the continuous presence of PNU-120596 (1st trace) the current has
only decayed to the 90% of its maximal amplitude, while after a
1295 ms exposure to choline without PNU-120596 (6th trace), the
remaining current was 37% of the maximal amplitude.
In summary, our experimental data suggests that PNU-120596
association is most significant to the fast desensitized (“D”) states.
From our experiments it is not clear whether association to the
slow inactivated (“S”) states does occur, but themodulator is unable
to cause opening, or PNU-120596 cannot even bind to this
conformation. If we model the simpler case, where we allow PNU-
120596 association only to fast desensitized states, we need to
extend Scheme 5 of the accompanying paper (Pesti et al.) with the
minimal model of PNU-120596 action. The topology we get is
shown in Scheme 5. The model constructed this way can reproduce
the characteristic biphasic pattern of currents evoked by choline
and PNU-120596 co-application, as well as the concentration- and
SXT-dependence of the currents. However, in order to test specific
hypotheses regarding the action of PNU-120596, and the interac-
tion between orthosteric and allosteric binding sites, we needed a
more complex model.
3.2. Modeling the effect of PNU-120596 on choline-evoked currents
3.2.1. General description of possible models
From the results of experiments we can conclude that the
interaction between orthosteric and allosteric ligands isScheme 5. Minimal model of PNU-120596 action. For the notatio
Please cite this article in press as: Szabo, A.K., et al., Mode of action of
receptors, Neuropharmacology (2014), http://dx.doi.org/10.1016/j.neuropasymmetric. The agonist affects modulator binding indirectly, by
causing desensitization. Because PNU-120596 can only associate to
desensitized receptors, while dissociates from resting ones, a
functional cooperativity emerges. On the other hand, modulator
binding seems to affect agonist binding directly, by either
increasing the affinity of the orthosteric binding site, or decreasing
its accessibility. The former would mean a change in the structure
of the binding site, which may accelerate association (which is less
likely), slow down dissociation (more likely), or both. Decreased
accessibility would mean that both association and dissociation
rates are reduced to a similar extent; in essence it means that the
modulator can trap agonist molecules in the binding site. The two
mechanisms are difficult to tell apart experimentally, therefore we
tested in simulations which one offers a plausible explanation for
our findings.
In order to address the state-preference of PNU-120596, we
needed to extend Scheme 5, by allowing association also to resting
and slow desensitized states (Scheme 6). The model thus had a
three-dimensional, cubic topology. For the sake of simplicity, we
chose to construct a MonodeWymaneChangeux-type allosteric
model. Each agonist binding step contributed equally to the
agonist-induced changes in gating rate constants. Another simpli-
fication was that e as in the models described above e we still
disregarded intermediate occupancy levels of the modulator
binding site, and considered only modulator-unbound and
modulator-bound states. Introduction of an additional set of
modulator-bound closed states (“C1x”) was necessary to reproduce
single channel bursting behavior. The values of the rate constants,
and their calculation are given in Supplementary Table 1. Alto-
gether the model had 54 states, and 212 rate constants, out of
which only 16 were free parameters. The rest of the rate constants
were calculated using the 8 allosteric factors. In addition, four
“symmetrical barrier factors”were introduced in order to be able to
test hypotheses regarding binding site accessibility more straight-
forwardly. Symmetrical barrier factors elevated the energy barrier
between two specific sets of states. They did not interfere with
detailed balance within the model, because forward and backward
rate constants were changed equally (see Supplementary Table 1
for details).
Partitioning of PNU-120596 molecules into/out of the mem-
brane phase seemed to be an essential contributor of current ki-
netics; therefore we included simulation of accumulation of then of conformational states and rate constants see Scheme 6.
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Scheme 6. A MonodeWymaneChangeux-type cubic model used in our simulations. The states are denoted by a three-character code. The first character indicates the confor-
mation: O (open), R (resting), D (desensitized), S (slow desensitized), and C (an unknown non-conducting conformation which we needed to suppose e as described below). The
second character indicates occupancy of the modulator binding sites (it is either vacant “0” or occupied “1”, and the last character indicates the number of bound agonist molecules
from 0 to 5. Transitions are denoted by a four-character code (except opening and closing transitions) as shown in the figure. The first character, a letter, indicates the nature of
transition: “a” and “b” are association and dissociation of agonist molecules, respectively; “c” and “d” are association and dissociation of the modulator, e, f, g, h, i, j, op (opening)
and clo (closing) are conformational transitions with no binding/unbinding involved. Only one of the six “op10x” “clo10x” transitions (modulator-bound resting-open transitions)
are shown for clarity (arrow and characters are in gray). The numbers indicate the location of individual transitions within the scheme along the three axes. The first digit indicates
presence or absence of PNU-120596 (z axis), the second digit indicates the conformation(s) in which, or between which the transition occurs (y axis), and the third digit indicates
the agonist occupancy level (x axis). The allosteric factors K, L, V, W and D express the interaction between agonist binding and conformational transitions, P, and Q, between
modulator binding and conformational transitions, and M expresses cooperativity between agonist and modulator binding. Although the free parameters discussed thus far fully
determine all rate constants, it was convenient to introduce some additional factors: they will be called “symmetrical barrier factors”, because both forward and backward
transitions are to be multiplied by these; in effect they modify the energy barrier of specific transitions. We introduced the following symmetrical barrier factors: zR, zD and zS
modifies the rate of PNU-120596 association/dissociation (i.e., transitions along the z axis) to states A, B and C states, respectively. The factor xRDS modifies the rate of choline
association to all PNU-120596-bound states. The additional non-conducting slow-entry-slow-exit states which were required for being able to reproduce burst lengths of
modulator-bound receptors were named C1x (C10eC15). These states could be connected to the PNU-120596-bound desensitized states (D1x states), the PNU-120596-bound open
states (O1x), or both. For the sake of simplicity we connected them only to desensitized states.
Table 1
The values of allosteric factors and symmetrical barrier factors in parameter sets “A”
to “D”.
A B C D
Q 1 0.15 0.15 0.15
M 1 1 2.1 1.25
xRDS 1 1 0.01 0.001
Allosteric factor Q quantifies the interaction between modulator binding and
desensitization. Q < 1 indicates that modulator-bound receptors favor desensitized
state, and that the modulator has higher affinity to desensitized receptors. Allosteric
factorM indicates the cooperativity between the agonist and the modulator. Values
>1 indicate that binding of one ligand increases affinity of the other binding site.
Symmetrical barrier factor: xRDS <1 indicates an increased energy barrier for
modulator-bound receptors (all conformations) along the x axis i.e., it slows down
agonist association and dissociation equally.
The parameter sets: A) basic model; no effect of the modulator on the resting e
desensitized equilibrium, no cooperativity between agonist and modulator binding
sites, both agonist and modulator association is unhindered. B) The modulator fa-
vors the desensitized state. C) Higher cooperativity, and moderately hindered
accessibility of the agonist binding site. D) Moderate cooperativity, and a strongly
hindered accessibility of the agonist binding site. Q4
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NP5391_proof ■ 1 February 2014 ■ 9/13molecules within the membrane phase. The dynamics of aqueous
([PNU]aq) and intramembrane ([PNU]mmb) PNU-120596 concentra-
tion was simulated using the differential equation:
d½PNUmmbðtÞ
dt
¼ ½PNUaq*partin  ½PNUmmb*partout
where partin and partout are the partitioning rate constants. We do
not know the distribution coefficient of PNU-120596 between the
membrane and aqueous solution. It is likely that the molecule is
accumulated within the membrane phase, because it is a lipophilic
molecule, but partitioning and distribution coefficients (logP and
logD) are only estimated for the watereoctanol distribution, which
can be much different from the membraneeaqueous phase distri-
bution. We chose the membraneeaqueous solution distribution
coefficient to be 1 (supposing ten-fold accumulation).
We first confirmed that partitioning of the modulator can ac-
count for the acceleration of the current onset upon pre-incubation
in PNU-120596 as described in Section 3.1.4. We tested how the
receptors would behave if affinity of the modulator was insensitive
to receptor conformation (parameter set “A” in Table 1). AssociationPlease cite this article in press as: Szabo, A.K., et al., Mode of action of the positive modulator PNU-120596 on a7 nicotinic acetylcholine
receptors, Neuropharmacology (2014), http://dx.doi.org/10.1016/j.neuropharm.2014.01.033
Fig. 7. Schematic drawing illustrating the mechanism of interaction between agonist
and PNU-120596 (see text for explanation).
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NP5391_proof ■ 1 February 2014 ■ 10/13to resting conformation was also possible in this case, and as ex-
pected, we observed a depletion of the first fast current component
(Fig. 6A, upper panel). We attempted to reproduce currents as
shown in Fig. 3 by modifying the affinity to resting conformation.
We did this by modifying the allosteric factor “Q” (see Scheme 6).
Decreasing “Q” slows down the association of the modulator, with
leaving the dissociation unaltered, while this modification is
balanced by promoting modulator-bound desensitization. To ach-
ieve an extent of decrease in the first current component that
matches data obtained in experiments (9.4%), we needed to
decrease Q at least to 0.15 (parameter set “B”), which corresponds
with association to resting conformation 44.4-fold slower (Fig. 6A
lower panel). The same extent of decrease in affinity was also
required to reproduce themagnitude of the fast current component
in re-application experiments, as it was shown in Section 3.1.5.
3.2.2. Simulation of the decay phase
As it has been shown in Section 3.1.3, when the agonist was
washed out in the continuing presence of the modulator, the decay
was slowed by almost an order of magnitude. The reason for this, as
we havementioned, can either be that modulator binding increases
the affinity of the orthosteric binding site, or that it “traps” agonist
molecules within the binding site. We tested both mechanisms in
simulations.
When association and dissociation rates of agonist molecules
were independent of modulator binding, the decay was inappro-
priate, much faster than in experiments (Fig. 6B, parameter set “B”).Fig. 6. Dependence of simulated current properties on specific parameters. Simulations of
association to resting state. The four traces show the initial part of simulated currents after
show simulations with parameter sets (see Table 1), “A” (equal association rate to resting
favored desensitized conformation upon modulator binding), respectively. (B) Choline disso
co-application of choline and PNU-120596, followed by a 2 s application of PNU-120596,
symbols) and concentrationerelative net charge (open symbols) plots in the presence of 1
currents are shown in gray. Thick lines show fits of the Hill equation to data points. (D) The fi
was investigated under more physiological circumstances: short (10 ms) pulses of the agon
Please cite this article in press as: Szabo, A.K., et al., Mode of action of
receptors, Neuropharmacology (2014), http://dx.doi.org/10.1016/j.neuropThe allosteric factor M (see Scheme 6) indicated the cooperative
interaction between agonist and modulator affinity. Introducing
cooperativity by elevating this factor only, did not prove sufficient
to reproduce the slowed decay. On the other hand, hindered
accessibility of the agonist in modulator-bound receptors also wasµ
currents show the occupancy of all open states as a function of time. (A) PNU-120596
15, 215, 415 and 615 ms of 10 mM PNU-120596 pre-incubation. Upper and lower panels
and desensitized states) and “B” (decreased association to resting state, balanced by
ciation from modulator-bound receptors. The simulated currents were evoked by a 1 s
using three parameter sets (see Table 1). (C) Concentrationerelative amplitude (filled
0 mM PNU-120596, for two parameter sets. Plots for modulatorefree agonist evoked
rst second of simulated 10 mM choline evoked currents when the behavior of the model
ist at a continuous presence of a lower concentration of PNU-120596 (1 mM).
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NP5391_proof ■ 1 February 2014 ■ 11/13insufficient in itself. (Hindered accessibility was achieved by
introducing the symmetrical barrier factor xRDS, i.e., by decreasing
both association and dissociation rate constants equally.) However,
when the two modifications were introduced in parallel, the slow
decay rate was reproduced. Strongly hindered accessibility
(xRDS ¼ 0.001) required only weak cooperativity: M ¼ 1.25 (this
means that the affinity of cholinewas increased 1.252¼1.56-fold by
modulator binding), while even a strong cooperativity (M > 2)
required radically restricted accessibility (e.g., M ¼ 2.1 and
xRDS ¼ w0.01; M ¼ 4.9 and xRDS ¼ 0.05). Simulations with two
combinations of M a xRDS are shown in Fig. 6B. The shape of the
curve (immediate exponential decay upon agonist removal) was
better reproduced by parameter set “D” (weak cooperativity,
strongly hindered access). A few other parameters also affected the
decay rate, but the single essential requirement was obviously
decreased agonist dissociation from modulator-bound receptors.
Both M and xRDS parameters affected agonist dissociation; the
extent of decrease is given byM2/xRDS.We can calculate, therefore,
that modulator-bound receptors had to have a 400e4000-fold
slower agonist dissociation than modulator-free receptors in all
parameter sets which reproduced the extent of decay found in
experiments. We propose that in the presence of PNU-120596, the
ability of choline to dissociate from its binding site is radically
reduced. This may be accompanied with a moderately increased
affinity for the agonist (i.e., cooperativity between orthosteric and
allosteric binding sites), but based on the simulations, hindered
accessibility, not increased affinity seems to be the predominant
mechanism.
We tested the concentrationeresponse behavior of the model in
the total absence of cooperativity (M¼ 1; parameter set “B”). Fig. 6C
(upper panel) illustrates concentrationeamplitude and concentra-
tionenet charge flux (area under curve; AUC) curves for choline
from simulated currents evoked in the presence of 10 mM PNU
120596. Concentrationeresponse curves in the absence of PNU-
120596 (from Fig. 8B of the accompanying paper) are also shown
in gray color for comparison. As we have shown there, the EC50
values for unmodulated currents were 1.24 mM and 135 mM for
peak amplitude and AUC, respectively (AUC calculated from the
first 200 ms). With choline and 10 mM PNU-120596 co-applied, the
EC50 values were 109 mM (amplitude; nH ¼ 3.01) and 121 mM (AUC;
nH ¼ 2.92). This means that for current amplitudes a 11.3-fold
apparent increase in choline affinity was observed even in the
“no-cooperativity” model (i.e., when there was no change in
microscopic agonist affinity). For the AUC plots the increase in
apparent affinity wasminimal (1.11-fold). This clearly shows that an
apparent increase in affinity can occur without binding of one
ligand actually affecting the affinity of the other binding site.
Introducing cooperativity (M¼ 2.1, parameter set “C”) did not cause
a large shift in the concentration response curve (Fig. 6C, lower
panel), the EC50 values were 85.5 mM (amplitude; nH ¼ 3.30) and
102.5 mM (AUC; nH ¼ 3.01). Although parameter set “D” imposed a
4.41-fold higher microscopic affinity on the model than parameter
set “C”, it only caused a 1.28-fold increase in macroscopic affinity. In
fact, compared to the huge difference between the concentratione
peak amplitude and the concentrationeAUC curves, the effect of
PNU-120596 on the AUC curves seems negligible even with
parameter set “D”, which caused the largest shift of the curves. The
reason for this, we believe, is the specific property of the a7 nAChR,
i.e., that maximal efficacy in terms of net charge flux is already
reached at submaximal agonist occupancy (Mike et al., 2000; Papke
et al., 2000). The concentrationepeak amplitude curve keeps
increasing even after reaching maximal net charge flux, but higher
agonist concentrations merely cause faster transfer of the same
amount of ions. We might phrase it this way: The increase in
apparent affinity caused by PNU-120596 merely unmasked thePlease cite this article in press as: Szabo, A.K., et al., Mode of action of
receptors, Neuropharmacology (2014), http://dx.doi.org/10.1016/j.neuropcharacteristic concentrationenet charge flux relationship of the a7
nAChR. A genuine increase in agonist affinity upon modulator
binding might have been present, but it probably only had a minor
effect on concentrationeresponse curves.
While the effect of the modulator on the EC50 (affinity) of the
agonist was questionable, its effect on amplitudes (efficacy) was
obvious. Thus far we have considered agonist affinity only; which
means studying relative amplitudes and relative charge fluxes. In
terms of absolute net charge flux, the effect of PNU-120596 is enor-
mous, and the differences between parameter sets are also great.
Fig. 6D illustrates the importance of the hindered agonist dissocia-
tion in a quasi-physiological situation with lower PNU-120596 con-
centration (1mMaqueous concentration), and a short (10ms) agonist
pulse (10 mM choline). We simulated the case when the modulator
had sufficient time beforehand to accumulate within themembrane
phase. The difference between unhindered (parameter sets “A” and
“B”), and hindered (parameter sets “C” and “D”) agonist dissociation
models was considerable. The extent of increase in charge flux
calculated over a 1 s period during and after a 10 ms pulse of 10 mM
cholinewas for unhindered agonist dissociationparameter sets 110.8
(“A”) and31.2 (“B”) times the charge carried by the current evoked by
choline alone, while for hindered agonist dissociation sets it was
much higher: 2392 (“C”) and 2001 (“D”). This also indicates that a
hindered agonist dissociation form modulator-bound receptors is a
fundamental element of the mechanism.3.3. Summary of the mechanism of PNU-120596 on a7 nAChRs
The two major observations regarding the mechanism of the
interaction between the agonist and the modulator are based on
the experiments described in Sections 3.1.3, 3.1.4, and 3.1.5, and on
the analysis by simulations in Sections 3.2.1 and 3.2.2: (1) Disso-
ciation of the agonist is hindered frommodulator-bound receptors.
(2) Affinity of PNU-120596 to resting state is low. Let us consider
what follows from these observations in a physiological situation,
where there is an ambient level of the modulator, and the agonist is
released in pulses. The essence of the mechanism is illustrated on a
schematic drawing (Fig. 7).
Before the agonist pulse, the vacant receptor cannot bind the
modulator, because it has lowaffinity to resting conformation. Once
the agonist pulse has started, the agonist can immediately bind to
the easily accessible modulator-unbound receptor. It causes the
receptor to desensitize, thereby providing access for the modulator.
Modulator binding induces a set of conformational states, which
causes agonist dissociation to slow down radically; in effect
modulator binding traps the agonist in its binding site. Once the
agonist has ultimately dissociated, the cycle is completed by
modulator dissociation, which allows the receptor to resume its
original resting state. Note that the agonist association is fast,
because it predominantly occurs to the highly accessible confor-
mation of the orthosteric site, but agonist dissociation is slow,
because it predominantly occurs from a low-accessibility site.
The trapped agonist cycle mechanism seems to be a require-
ment for type II PAM action, as we have seen from simulations with
parameter sets “B” to “D”. Without introducing decreased agonist
accessibility, the current had only a minor delayed component after
the agonist had been removed (Fig. 6D).4. Conclusions
We investigated the mechanism of modulation of a7 nAChR
function by PNU-120596 in experiments, and tested various hy-
potheses for possible mechanisms by kinetic simulations. Our
major conclusions are as follows:the positive modulator PNU-120596 on a7 nicotinic acetylcholine
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NP5391_proof ■ 1 February 2014 ■ 12/13The current evoked by choline in the presence of PNU-120596
was biphasic. The first phase had a fast onset and decay, and it
reflected unmodulated choline-evoked current. The onset of the
first phase was essentially unchanged evenwhen PNU-120596 was
pre-applied, although in this case the fast decay of the first phase
could not be seen, because the two phases partially merged.
The unchanged fast onset suggested that association to resting
channels was hindered. Kinetic modeling suggested that affinity to
resting conformation must be at least 44-fold lower than to
desensitized state. We propose, that when receptors are activated
by agonistemodulator co-application, they typically desensitize
before they bind modulator molecules.
Application of PNU-120596 after prolonged (several seconds
long) choline perfusion evoked currents with decreased amplitude.
This confirms the existence of PNU-120596-insensitive slow
desensitized state(s). We observed that gating into PNU-120596-
insensitive desensitized states was faster in the absence of the
modulator.
The interaction of the agonist and modulator revealed that
dissociation of choline molecules was radically hindered by bound
modulator molecules. In kinetic simulations agonist dissociation
had to be at least w400- to 4000-fold slower from modulator-
bound receptors to reproduce experimentally observed decay rates.
The large apparent increase in agonist affinity upon PNU-
120596 binding in simulations did not require actual coopera-
tivity between agonist and modulator binding sites on the level of
rate constants, i.e., modification of microscopic affinity (although it
also did not exclude it). Experimental current forms were best
reproduced by a very week cooperativity.
We propose an explanation for type II PAM mechanism of ac-
tion, based upon two critical observations: i) choline dissociation
fromPNU-120596-bound channels is hindered, and ii) PNU-120596
affinity to resting channels is low. We propose, that even in the
continuous presence of the modulator, its association is minimal,
because the receptors are in resting state. Whenever the concen-
tration of the agonist is increased, a cycle of events occurs: the
agonist binds to an unhindered binding site, and desensitizes the
receptor, the modulator can bind to desensitized conformation, and
it induces a set of conformational states, in which opening of the
pore is energetically more favorable, and in which the agonist is
kept trapped in its binding site. This produces a prolonged period of
intense activity, when the effect of the agonist is both prolonged
and enhanced (i.e., the open probability is increased). Once the
agonist has finally dissociated, the modulator also dissociates, and
the cycle is terminated. The requirements for this “trapped agonist
cycle” mechanism are the following: The receptor needs to have
two ligands with a specific type of interaction: Binding of “ligand A”
(the agonist in this case) must increase the accessibility of “ligand
B” (the modulator), while binding of “ligand B” must decrease the
accessibility of “ligand A”. The mechanism does not require that the
orthosteric and allosteric ligands actually modify each other’s
microscopic affinity. In situations, where the agonist comes in short
pulses (as it is probably the case for in vivo receptors) and only the
modulator is present continually, this mechanism provides an
exceptionally effective way of enhancing the signal.121
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